Recombinant human bone morphogenetic protein-7 ineffective in spinal fusion vs. control .
This report has been verified
by one or more authors of the
original publication.
Union Rate and Complications in Spine Fusion with Recombinant Human Bone Morphogenetic Protein-7: Systematic Review and Meta-Analysis
Global Spine J. 2016 Mar;6(2):124-326 studies with 442 patients were included in this analysis which was conducted in order to determine if recombinant human bone morphogenetic protein-7 (rhBMP-7) was safe and effective in promoting bone formation in spinal fusion. The findings of this study question the clinical relevance of this treatment as comparable rates of union, complications, postoperative back and leg pain, and revision were reported between rhBMP-7 and control groups. One case of a new onset of cancer was also reported in the rhMBP-7 group.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
